Detectable Laboratory Abnormality Is Present up to 12 Months Prior to Diagnosis in Patients with Crohn’s Disease
Background and Aims
Patients with inflammatory bowel disease (IBD) often have subjective symptoms for months or years prior to their diagnosis. Blood tests taken prior to diagnosis may provide objective evidence of duration of pre-diagnosis disease. We aim to describe the pre-diagnosis laboratory pattern of patients with IBD.
A total of 838 patients diagnosed with IBD between 01/01/1996 and 01/03/2014, with pre-diagnosis laboratory testing available, contributed data for analysis. C-reactive protein, erythrocyte sedimentation rate, hemoglobin level, mean cell volume (MCV) platelet count, white blood cell count, neutrophil count, albumin level, ferritin level, serum iron level, alanine transaminase level, and fecal calprotectin were examined in the 24 months leading up to diagnosis and compared to baseline data taken between 24 and 36 months prior to diagnosis.
For patients with Crohn’s disease, a significant drop in serum albumin and MCV levels and a significant rise in platelet count were observed between 115 and 385 days prior to diagnosis (p < 0.01, two-tailed t test). For patients with ulcerative colitis, a significant change in albumin level, MCV, hemoglobin level, platelet count, and serum iron level was observed at diagnosis (p < 0.01, two-tailed t test) but was not detectable before.
These data provide objective evidence of duration of delay between disease onset and diagnosis in a cohort of patients with IBD. Expediting diagnostic testing in patients presenting with symptoms consistent with IBD, who also have abnormal laboratory results, may reduce diagnostic delay, speed access to therapy, and improve clinical outcomes.
KeywordsCrohn’s disease Biomarker Pre-diagnosis
Erythrocyte sedimentation rate
Inflammatory bowel diseases
Mean cell volume
White blood cell count
JRI performed data collection, performed statistical analysis, drafted the manuscript, and was involved in the final review of the manuscript. GRS performed data collection and was involved in the final review of the manuscript. JDD performed statistical analysis and was involved in the final review of the manuscript. EF, KH, LAS, AA, and DL performed data collection and were involved in review of the manuscript.
This work was supported by peer-reviewed grants from the National Health and Medical Research Council (Australia) and the Royal Brisbane and Women’s Hospital Foundation.
Compliance with ethical standards
Conflict of interest
GRS has worked on advisory boards for and received consulting fees from Abbvie, Janssen, Ferring, Takeda, and Amgen. JRI, EF, KH, LAS, JD, DL, and AA have no conflict of interest to declare.
- 12.Lochhead P, Khalili H, Ananthakrishnan AN, Richter JM, Chan AT. Association between circulating levels of C-reactive protein and Interleukin-6 and risk of inflammatory bowel disease. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2016;14:818–824.e6. https://doi.org/10.1016/j.cgh.2016.01.016.Google Scholar
- 14.Aho K, Heliövaara M, Maatela J, Tuomi T, Palosuo T. Rheumatoid factors antedating clinical rheumatoid arthritis. J Rheumatol. 1991;18:1282–1284.Google Scholar
- 18.R Core Team. R: A Language and Environment for Statistical Computing, R version 3.4.4. Vienna, Austria: R Foundation for Statistical Computing; 2018. https://www.R-project.org/. Accessed 12 Nov 2018.
- 20.Champely S. PWR: Basic Functions for Power Analysis, R package version 1.2-1; 2017. https://CRAN.R-project.org/package=pwr. Accessed 12 Nov 2018.
- 21.Cohen J. Statistical Power Analysis for the Behavioral Sciences. Hillsdale: L. Erlbaum Associates; 1988.Google Scholar
- 24.OECD Statistics. http://stats.oecd.org/. Accessed June 20, 2017.
- 26.Inflammatory bowel disease|Guidance and guidelines|NICE. https://www.nice.org.uk/guidance/qs81. Accessed June 21, 2016.
- 27.English|World Gastroenterology Organisation. http://www.worldgastroenterology.org/guidelines/global-guidelines/inflammatory-bowel-disease-ibd/inflammatory-bowel-disease-ibd-english. Accessed June 21, 2016.
- 36.Heianza Y, Arase Y, Fujihara K, et al. Longitudinal trajectories of HbA1c and fasting plasma glucose levels during the development of type 2 diabetes: The Toranomon Hospital Health Management Center Study 7 (TOPICS 7). Diabetes Care. 2012;35:1050–1052. https://doi.org/10.2337/dc11-1793.CrossRefGoogle Scholar